As Pandorum Technologies’ bioengineered ‘liquid cornea’, Kuragenx, is about to enter a first-in-human study for vision restoration in patients suffering from corneal blindness, the company is extending its proprietary technology platform to develop advanced exosome-based therapeutics for lung and liver regeneration.